Gene Expression Atlas home | about the project | faq | feedback | blog | das | api | help
VTCN1
REST API REST API
Homo sapiens
VTCN1 is differentially expressed in 138 experiments: 72 organism parts: mammary gland, bone marrow, ... (70 more);, 73 disease states: normal, breast carcinoma, ... (71 more);, 32 cell types 223 cell lines 11 compound treatments and 50 other conditions.
Synonyms B7-H4, B7X, B7S1, B7H4, FLJ22418
Orthologs VTCN1 (Gallus gallus)   VTCN1 (Danio rerio)   Vtcn1 (Mus musculus)   VTCN1 (Bos taurus)   Vtcn1 (Rattus norvegicus)   vtcn1 (Xenopus laevis)   VTCN1 (Canis familiaris)   (Compare orthologs)
InterPro Term Ig_V-set, Ig_sub, Ig-like
Gene Ontology Term plasma membrane, protein binding, receptor binding, integral to membrane, negative regulation of T cell activation
UniProt Accession Q5T2L0, Q6P097, Q7Z7D3
Search EB-eye ENSG00000134258
Show more properties
Experimental Factors
Organism part

studied in E-GEOD-803, E-GEOD-15765, E-AFMX-5, E-GEOD-6573, E-MTAB-24, ... (19 experiments)

3
1
Number of published studies where the gene is over/under expressed compared to the gene's overall mean expression level in the study.

anatomogram

Cell line

studied in E-GEOD-17482, E-GEOD-5258, E-GEOD-19639, E-GEOD-29119, E-GEOD-2450, ... (18 experiments)

Factor Value U/D Experiments
MCF7
2
E-GEOD-5258, E-MTAB-37
HCC2157
2
E-MTAB-37, E-MTAB-62
HCC38
2
E-MTAB-37, E-MTAB-62
MCF-7
2
E-GEOD-20081, E-GEOD-19639
MDA468
2
E-MEXP-440, E-MTAB-62
MDAMB175VII
2
E-MTAB-37, E-MTAB-62
217 more value(s).


Cell type

studied in E-GEOD-10797, E-GEOD-18811, E-AFMX-5, E-MTAB-24, E-GEOD-29119, ... (19 experiments)

Factor Value U/D Experiments
CD34+
2
E-AFMX-5, E-TABM-145
2
E-TABM-145, E-TABM-130
CD4+ T cell
7
1
E-MTAB-24
n/a
1
E-MTAB-24
primary human mammary epithelial cells
1
E-GEOD-29119
fetal RPE
1
E-GEOD-18811
26 more value(s).


Disease state

studied in E-GEOD-3307, E-GEOD-6872, E-GEOD-15960, E-GEOD-1577, E-TABM-15, ... (31 experiments)

Factor Value U/D Experiments
prostate carcinoma
2
E-MEXP-2034, E-MEXP-1327
monoclonal gammopathy of undetermined significance (MGUS)
1
E-GEOD-2113
Decidualised
1
E-MTAB-680
Partially decidualised
1
E-MTAB-680
acute malaria, natural infection Cameroon
1
E-GEOD-5418
ovarian tumor, mucinosus
1
E-MTAB-62
67 more value(s).


Compound treatment

studied in E-GEOD-5824, E-GEOD-6462, E-GEOD-3113, E-GEOD-7307, E-GEOD-20081 ... (5 experiments)

Factor Value U/D Experiments
ethanol
3
1
E-GEOD-3113
Cxcl12
1
E-GEOD-7307
epidermal growth factor
3
1
E-GEOD-6462
estradiol
3
1
E-GEOD-20081
no estradiol
1
E-GEOD-20081
rapamycin
1
E-GEOD-5824
5 more value(s).


Agent

studied in E-GEOD-19519

Factor Value U/D Experiments
thapsigargin
1
E-GEOD-19519
tunicamycin
1
E-GEOD-19519


Biosource provider
studied in E-GEOD-20559

BioSourceProvider
studied in E-GEOD-19519

Blood/non-blood meta-groups
studied in E-MTAB-62

Bmngrd
studied in E-GEOD-20194, E-GEOD-16716

Cell treatment
studied in E-MEXP-1192

Cellular component
studied in E-GEOD-1400

Clinical history
studied in E-GEOD-22097, E-GEOD-19743, E-GEOD-7967, E-GEOD-16363

Clinical info
studied in E-GEOD-19743, E-MTAB-37, E-GEOD-19348, E-GEOD-21589, E-GEOD-18995, ... (7 experiments)

Clinical treatment
studied in E-GEOD-6532

coriell cell line repository identifier
studied in E-GEOD-19519

Developmental stage
studied in E-MEXP-2359, E-GEOD-2666, E-MEXP-303, E-MTAB-62

Dfs follow up
studied in E-GEOD-22541

Disease staging
studied in E-GEOD-19743, E-GEOD-3325, E-GEOD-22541, E-GEOD-21138

Estrogen receptor status
studied in E-GEOD-6532

family id
studied in E-GEOD-19519

Genetic modification
studied in E-GEOD-8023, E-MTAB-73, E-GEOD-20847, E-MTAB-108

Genotype
studied in E-GEOD-17476, E-TABM-601, E-GEOD-17347, E-GEOD-19293

369 groups
studied in E-MTAB-62

4 groups from blood to incompletely diff
studied in E-MTAB-62

96 groups
studied in E-MTAB-62

Growth condition
studied in E-TABM-263

Histology
studied in E-GEOD-16194

Individual
studied in E-MTAB-197, E-TABM-325, E-MEXP-2069, E-TABM-666, E-GEOD-19519, ... (16 experiments)

Infection
studied in E-MEXP-561

Injury
studied in E-GEOD-19743

Karyotype
studied in E-GEOD-22056

Labeling
studied in E-LGCL-5

Localisation of metastases
studied in E-GEOD-22541

15 meta groups
studied in E-MTAB-62

4 meta groups
studied in E-MTAB-62

6 meta groups
studied in E-MTAB-62

Molecular subtype
studied in E-GEOD-21653

Organism
studied in E-TABM-84

Organism status
studied in E-GEOD-19188

Performer
studied in E-LGCL-5

Phase
studied in E-GEOD-4888

Progesterone receptor status
studied in E-GEOD-6532

Protocol type
studied in E-GEOD-22097, E-GEOD-21837, E-GEOD-19246

Qrt pcr ereg dct
studied in E-GEOD-5851

RNAi
studied in E-GEOD-3697

Sample preparation
studied in E-GEOD-16728

sampleID
studied in E-GEOD-24283

Sampling time point
studied in E-GEOD-19743, E-GEOD-17400

Subtype
studied in E-GEOD-24283

Survival time
studied in E-GEOD-19188

Transfection
studied in E-GEOD-14680

Treatment
studied in E-GEOD-19246, E-GEOD-12198

Tumor grading
studied in E-GEOD-3494, E-GEOD-1561, E-GEOD-4922

Vehicle
studied in E-GEOD-5258

Processing time: 0.509 secs.
 
Gene Expression Atlas 2.0.11.1- 12/23/11 3:09:34 PM